Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Assets (2017 - 2025)

Aclaris Therapeutics has reported Non-Current Assets over the past 9 years, most recently at $64.1 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $64.1 million for Q4 2025, down 32.03% from a year ago — trailing twelve months through Dec 2025 was $313.3 million (up 38.27% YoY), and the annual figure for FY2025 was $64.1 million, down 32.03%.
  • Non-Current Assets for Q4 2025 was $64.1 million at Aclaris Therapeutics, down from $74.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ACRS hit a ceiling of $102.7 million in Q2 2023 and a floor of $11.1 million in Q3 2022.
  • Median Non-Current Assets over the past 5 years was $48.4 million (2021), compared with a mean of $55.9 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 80.84% in 2022 and later skyrocketed 761.61% in 2023.
  • Aclaris Therapeutics' Non-Current Assets stood at $46.2 million in 2021, then plummeted by 50.09% to $23.0 million in 2022, then surged by 197.44% to $68.5 million in 2023, then skyrocketed by 37.68% to $94.4 million in 2024, then plummeted by 32.03% to $64.1 million in 2025.
  • The last three reported values for Non-Current Assets were $64.1 million (Q4 2025), $74.9 million (Q3 2025), and $84.9 million (Q2 2025) per Business Quant data.